Home Health VNA
IM/SC Medication Clinical Fact Sheet

Medication Name Generic: Dupilumab

Medication Name Brand: Dupixent

Risk Level: n/a

Med Class: Monoclonal antibody - Interleukin-4 receptor alpha antagonist

Use:

- **Atopic Dermatitis:** Treatment of moderate-to-severe atopic dermatitis when disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable
- **Asthma:** Add-on maintenance treatment for patients with moderate-to-severe asthma characterized by eosinophilic phenotype or with oral corticosteroid dependent asthma.
- **Adult Chronic Rhinosinusitis with nasal polyposis:** Add-on maintenance with inadequately controlled chronic rhinosinusitis with nasal polyposis.

Ages:

- Pediatrics – dependent on use case
    - Atopic Dermatitis – 6 – 17 years of age
    - Asthma – 6 – 17 years of age
- Adults – 18+

Instructions:

- Approved for subcutaneous injection only
- <u>PEDIATRIC PATIENTS – AGES 6 – 11</u>
    - Dose should be administered by a health care provider OR
    - By a caregiver who has been trained in administering medication
- If using prefilled syringe/pen that has been refrigerated, place syringe on flat surface, without removing needle cap and allow to warm to room temperature before injecting medication:
    - 30 minutes for 100-200mg
    - 45 minutes for 300mg
- DO NOT warm medication by placing in microwave, placing it in warm water or any other method.
- DO NOT shake syringe/pen.
- Check expiration date.
- Prefilled syringe/pen can be stored either in the refrigerator or at room temperature up to 14 days.
- Keep prefilled syringes/pens in original packaging and protect from light.
- Liquid should be clear and colorless or slightly yellow.

- DO NOT give if:
    - Past expiration date.
    - Liquid has been frozen.
    - Syringe/pen is cracked.
    - Liquid is cloudy or contains small particles.
- May be injected in usual SQ injection sites, except within 2 inches (5 centimeters) of naval.

Dosage: Refer to package insert for loading and maintenance dose rates

- Pediatrics – dependent on use case
    - Atopic Dermatitis – 6 – 17 years of age
    - Asthma – 12- 17 years of age
    - Asthma – 67 – 11 years of age: based on body weight
- Adults – 18+

Precautions:

- Inform MD if patient is taking any oral or inhaled corticosteroid medications
- If receiving dupliumab for atopic dermatitis, inform MD if patient also has asthma
- Pregnancy: Tell MD if patient is pregnant, or plans to become pregnant
- Hypersensitivity reactions have occurred – discontinue treatment and notify MD if any s/sx of hypersensitivity occur.
- Conjunctivitis and keratitis – report new or worsening sx.
- Eosinophilic Conditions – vasculitis rash, worsening pulmonary symptoms, neuropathy – especially if reducing oral corticosteroids.
- Parasitic (Helminths) infections – parasitic worms i.e. ringworm, hookworm, etc.. Notify MD if patient becomes infected.

Missed Dose Instructions

- If every other week dose or every 4 week dose is missed, instruct to administer injection within 7 days from missed dose, then resume schedule.
- If missed dose not administered within 7 days of missed date, administer the dose, then start a new dosing schedule.
-

Desired effects:

- Decrease symptoms of atopic dermatitis
- Prevent wheezing, SOB, coughing, chest tightness associated with asthma
- Treat symptoms of Adult Chronic Rhinosinusitis with nasal polyposis

Side effects:

- **Atopic Dermatitis:** Most common adverse reactions (incidence ≥1%) are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye.

- **Asthma:** Most common adverse reactions (incidence ≥1%) are injection site reactions, oropharyngeal pain, and eosinophilia.
- **Chronic Rhinosinusitis with Nasal Polyposis**: Most common adverse reactions (incidence ≥1%) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

Contraindications:

- Allergy to dupliumab or any ingredients in injection.

First Dose Allowed in Home: **Y**/n

Source(s):

FDA. (2021, October). Dupixent (dupilumab), for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761055s031lbl.pdf

Medical News Today. (2022, May 7). Dupixent (dupliumab). Retrieved from https://www.medicalnewstoday.com/articles/326617#about

National Institutes of Health, National Library of Medicine. (2022). Dupilumab Injection. Retrieved from https://medlineplus.gov/druginfo/meds/a617021.html

Regeneron Pharmaceuticals, Inc. (2022, May 20). FDA approves Dupixent (dupliumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis. Retrieved from https://www.prnewswire.com/news-releases/fda-approves-dupixent-dupilumab-as-first-treatment-for-adults-and-children-aged-12-and-older-with-eosinophilic-esophagitis-301552282.html

Notes: Only drugs listed as First Dose Allowed may be given in the home as a first dose and are considered for a first dose on a case by case basis by the IV Program Manager
The IV Manager and/or Clinical Director must be consulted before a first dose referral is accepted

Risk Levels:
n/a = Routinely given; Clinician must be approved to administer IV medications
1= IV Program Mgr or Clinical Director approval before referral is accepted
2= IV Program Mgr notification; Clinicians must review Special Instructions